An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

Exclusion Criteria

• •1. Permanently discontinued BMN 111 or placebo prior to completion of Study 111-206
• •2. Have a clinically significant finding or arrhythmia on ECG that indicates abnormal cardiac function or conduction or QTc-F \> 450 msec
• •3. Require any investigational agent (except BMN 111) prior to completion of study period
• •4. Current therapy with antihypertensive medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac glycosides, systemic anticholinergic agents, GnRH agonists, any medication that may impair or enhance compensatory tachycardia, diuretics, or other drugs known to alter renal or tubular function
• •5. Pregnant or planning to become pregnant (self or partner) at any time during the study
• •6. Concurrent disease or condition that, in the view of the investigator, would interfere with study participation or safety evaluations, for any reason
• •7. Have a condition or circumstance that, in the view of the investigator, places the subject at high risk for poor treatment compliance